Pharmaceutical and life-science teams are under steady pressure to bring research spaces online quickly, without cutting corners on compliance. A new joint venture between Total Clean Air (TCA) and Vanguard Healthcare Solutions aims to close that gap by offering cleanrooms that are built off-site, validated to global standards, and ready for installation almost anywhere.
Modular Clean Air (MCA) made its first public appearance at Lab Innovations 2025 in Birmingham. The company introduced its complete cleanroom series, including a walk-through demonstrator showing how fully assembled units can be delivered, positioned, and commissioned faster than traditional builds. Shorter timelines count for manufacturers dealing with time-sensitive production schedules, and labs preparing for new R&D programs.
At the event, TCA Chief Executive Phillip Godden explained why speed has become such a defining requirement. During COVID-19, cleanroom demand rose sharply as vaccine developers worked to expand capacity. “We proved that we could deliver at speed, including a 2,700 sqm cleanroom in under 12 weeks,” he said. That experience shaped MCA’s current approach: factory-built modules designed to meet UKAS 17025, ISO 14644, and Good Manufacturing Practice (GMP) requirements before they ever reach a customer’s site.
The range includes self-contained single-story units, relocatable cleanrooms for sites that need temporary or flexible infrastructure, and large multi-story systems designed for industrial-scale processes. All three series are engineered and built in Britain, with compliance checks completed before shipment.
Vanguard’s contribution centers on its long record of delivering modular clinical facilities to NHS sites under tight timelines. CEO Chris Blackwell-Frost said the same principles apply to pharma and biotech environments, where controlled conditions and predictable delivery are equally important. By combining technical clean-air engineering with an established off-site construction model, the joint venture positions MCA as a reliable route to quicker validation and faster operational readiness.
MCA’s approach offers a practical way to remove delays from the build cycle while keeping compliance at the forefront.
Article source: Pharmaceutical Manufacturer Media
